{
  "ticker": "TLX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02971537",
  "id": "02971537",
  "pages": 6,
  "price_sensitive": true,
  "date": "20250722",
  "time": "1635",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250722/pdf/06m11jmm69289p.pdf",
  "summary": "- **Revenue Performance**:  \n  - Q2 2025 unaudited revenue of $204M, up **63% YoY**.  \n  - FY 2025 revenue guidance reaffirmed at **$770M\u2013$800M**.  \n\n- **Product Milestones**:  \n  - **Gozellix** launched in U.S. with **HCPCS Level II code** secured (effective 1 Oct 2025).  \n  - **Illuccix** Phase 3 China study enrollment completed; marketing authorization filing expected Q4 2025.  \n  - **ProstACT Global Phase 3 trial**: All 30 patients consented for Part 1; regulatory approvals secured for China, Japan, and Canada.  \n\n- **Pipeline Updates**:  \n  - **TLX250 (kidney cancer)**: STARLITE-1 trial enrolling; pivotal monotherapy trial planned ex-U.S.  \n  - **TLX592 (prostate cancer)**: Phase 1 HREC application submitted in Australia.  \n  - **TLX090 (bone pain)**: IND submitted for Phase 1 bridging study.  \n\n- **Regulatory/Legal**:  \n  - **SEC subpoena** received related to prostate cancer therapeutic disclosures. Telix is cooperating; no impact on commercial products noted.  \n  - **Zircaix (TLX250-CDx)**: PDUFA date remains **27 Aug 2025**.  \n\n- **Manufacturing Expansion**:  \n  - **GMP facilities** operational in **Yokohama (Japan)** and **Brussels (Belgium)**.  \n\n**Key Omissions**: Routine operational updates, forward-looking disclaimers, and non-material pipeline details excluded.",
  "usage": {
    "prompt_tokens": 4329,
    "completion_tokens": 351,
    "total_tokens": 4680,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-22T07:03:00.255235"
}